"Cocktail" of young blood helped stop the development of Alzheimer's

The idea that young blood possesses almostmagical properties, took place at the dawn of the emergence of modern society. However, some experiments in this area are still ongoing. Of course, nobody rises to the medieval ceremonies with blood transfusion of infants. But not so long ago, the Californian company Alkahest was able to prove during a preliminary test phase that specially prepared plasma of young blood helps to cope with the manifestations of Alzheimer's disease.

How blood can cure Alzheimer's

Alkahest is developing methodstreatment of neurodegenerative diseases for several years. Scientists of the company make a very great emphasis on special proteins called chronokines. Chronokines are found in blood plasma and, according to some data, have a positive effect on the central nervous system, restoring the functioning of brain neurons and contributing to stem cell regeneration processes. It is also known that the content of chronokines changes with age, significantly decreasing in old age. Alkahest scientists decided to fill this gap.

This is interesting: Gene therapy will be used to treat Alzheimer's disease.

In recent studies, scientists scoreda group of 40 patients suffering from Alzheimer's disease. Scientists wanted to check whether their predictions were confirmed that if a person receives a fraction of blood plasma with GRF6019 chronokines placed in it, this will slow down the course of the disease. It is worth noting that this is the second phase of testing and during the first in laboratory animals the result was positive. This time, all 40 participants in the experiment were injected intravenously with therapeutic plasma with GRF6019 chronokines over five days. After 12 weeks, the procedure was repeated. In this case, before and after the course of treatment, patients underwent several of the most common tests to assess the depth of cognitive impairment in Alzheimer's disease and senile dementia.

As a result, it turned out that after 12 weeksthe treatment indicators of patients in these tests remained at the same level. This may seem like a bad result, but in fact it is far from it. The fact is that in 12 weeks the test results should have decreased, since during this time the processes of brain degeneration in the normal course of the disease simply could not slow down.

Our results indicate potential benefits.plasma protein fractions GRF6019 in slowing the progression of Alzheimer's disease, says Alkahest head Carol Nikolic. The development of effective treatments for this and other neurodegenerative diseases has been virtually unsuccessful for many decades. GRF6019 is aimed at eliminating several mechanisms that underlie the development of the process. Such as, for example, uncontrolled death of nerve cells.

You can discuss this and other news in our chat in Telegrams.